{"analyses":[{"ciLowerLimit":"0.295","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.451","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","otherAnalysisDescription":"Analysis is performed by randomization strata of HRD classification by CTA, best response, and penultimate platinum progression-free interval.","pValue":"<0.0001","paramType":"Cox Proportional Hazard","paramValue":"0.365","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"8.3","upperLimit":"11.4","value":"10.8"},{"groupId":"OG001","lowerLimit":"5.3","upperLimit":"5.5","value":"5.4"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"375"},{"groupId":"OG001","value":"189"}],"units":"Participants"}],"description":"Progression-free survival by Investigator (invPFS) is defined as the time from randomization to disease progression, according to RECIST v1.1 criteria as assessed by the investigator, or death due to any cause, whichever occurs first. Progressive disease is defined using Response Evaluation Criteria In Solid Tumors Criteria (RECIST v1.1), as a 20% increase in the sum of the longest diameter of measurable lesions, an unequivocal increase in existing non-measurable lesion(s), or the appearance of unequivocal new lesion(s).","dispersionType":"95% Confidence Interval","groups":[{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG000","title":"Rucaparib 600 mg Tablets"},{"description":"Taken orally twice daily (continuous 28 day treatment cycles)","id":"OG001","title":"Placebo Tablets"}],"paramType":"MEDIAN","populationDescription":"Intent-to-treat: All patients randomized","reportingStatus":"POSTED","timeFrame":"Every 12 calendar weeks (within 7 days prior is permitted) after start of treatment until treatment discontinuation due to disease progression. Total follow-up was up to approximately 3 years.","title":"Disease Progression According to RECIST Version 1.1, as Assessed by the Investigator, or Death From Any Cause (Investigator Progression Free Survival as Per invPFS)","type":"PRIMARY","unitOfMeasure":"Months"}